If you honestly believe that, you're as dumb as they come. Sales has been decimated, continues to be trimmed and will be half of its current size in five years.
16,000 employees to cut.
- Thread starter Anonymous
- Start date
-
- Tags
- None
If you honestly believe that, you're as dumb as they come. Sales has been decimated, continues to be trimmed and will be half of its current size in five years.
They are trying to figure out how to trim the MRL budget by 10%. It is early stage stuff.
It is actually going to be more than 10% at MRL - clinical operations will be the first to go then data management (well what is left of it) and then biostats. Patient recruitment specialist positions will also go by the way side; clin pharm will not be hit so hard. Also expect cuts in project management at MRL. New clinical operations will be like at SP so anyone who does not have protocol writing experience will be gone. Only the most senior people from MRL and SP data management will be kept on. That is the news so far.......
it's not like project management at SP had anything to do with protocol writing......
Cut Tom Lyons
Cut Tom Lyons
Cut Tom Lyons
= 16,000 employees can stay!!!
Cut Tom Lyons
Cut Tom Lyons
= 16,000 employees can stay!!!
Not true. Everything is moving along. Keeping a focus on long term project in clinical. It is the future.
Time to cut those 'tagalongs' over in Marketing and Sales. Long over due.
You'd be no where without marketing and sales, especially sales....you think products sell themselves?
Regardless, as a former SP rep, I can't wait until the next round of layoffs....Merck's culture has no appeal. Just waiting for severance, as I'm close to early retirement.
Can you say 'contract sales?' it is the way of the future. No overhead for cars, benefits and if you whine-they can dump you. Amen. Capitalism at its best.
You sound like you are a longtimer at Merck and very comfortable in your position. Don't you realize that the pipeline at Merck is dry so who will be employed??? Better to go with an outsourcing model which means lay offs are coming to MRL. Better get a reality check NOW..............
Maybe we can go with contract R&D...there's already some of that. Like you said, capitalism at its finest
The message is clear - or is it? The R&D budget will remain high - but does that mean that existing R&D job will remain? Everything in this industry is getting outsourced - sales, research, manufacturing, administration, maintenance. It is unclear what exactly Merck needs or wants to be excellent at in order to survive, let alone thrive. And if all that is left are those that manage the outsourced doers, where are they getting their experience in order to know what the hell they are managing?
I would like to see some accountability in R&D.
They have not produced any revenue generating products in who knows how long, and the leaders continue to get significant bonuses.
They have not produced any revenue generating products in who knows how long, and the leaders continue to get significant bonuses.
Oh, it is all the researchers fault. How about holding management accountable for the 'targets' chosen. Most lab managers don't get a choice on the project. It comes down from above based on Marketing
To all the geniuses that want to outsource R&D, how many Merck drugs have been brought in to Merck via outsourcing? How many biotechs/academic labs are discovering blockbusters, or any revenue generating drugs? Don't know? That's because it has yet to be proven that outsourcing R&D is any better than doing the hard work of drug discovery in-house.
Nobody is coming up with anything these days.
Nobody is coming up with anything these days.
Overpaid R+D, no accountability and a sense of entitlement in the labs. Put their jobs on the line-then you will see some real research come out of them.
We have a couple of medical clients looking for pharma reps with a B2B background and less than five years of pharma sales experience and interested in moving into medical hospital sales. Yes, there really are medical companies looking for pharm reps! If interested, send your paper to contact @ cpr4sales. co.m
You're making stuff up and obviously have no idea how research works and doesn't work. Like the other post said, who should we compare Mrk R&D too? Who is the gold standard? We just bought a bunch of crap from sgp, which supposedly had a great R&D.
Imo, putting down the only people that can pull Mrk out of the hole is not very smart business.
We shall see. Pfizer seems to be taking your advice, slashing research to make the street happy for today. I believe investing in r&d is the only way to grow the business long term and it seems that The new ceo thinks the same thing. I'd put my money on Mrk over the long run, and I am.